Table 3. Summary of studies comparing in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against extended-spectrum -lactamase-producing Enterobacterales from different geographical regions worldwide.
| Study | Geographic location | Susceptibility testing method | Inclusion criteria | Collection years | Number included | Susceptible to MEM, n (%) | Susceptible to CZAn, (%) | Susceptible to C/T, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alatoom et al,17 2017 | Abu Dhabi, UAE | Etest | Resistant to % 1 agent from % 3 antimicrobial classes | 2015?"2016 | 31 | NA | 29 (93.5) | 30 (96.8) | |||||||
| Sader et al,18 2020 | 70 medical centers, USA | Broth microdilution | ESBL-producing Enterobacterales from patients hospitalized with pneumonia | 2017?"2018 | 285 | 283 (99.3) | 285 (100) | 219 (76.8) | |||||||
| Viala et al,19 2019 | Montpellier, France | Etest | 3rd G cephalosporin resistant Enterobacteriaceae | 2017 | 62 | NA | 60 (97) | 34 (65) | |||||||
| Araj et al,20 2020 | Beirut, Lebanon | MIC gradient Strip Test | MDR and ESBLs E. coli and K. pneumoniae | 2017?"2018 | 199 | NA | NA | 159 (79.9) | |||||||
| Hirsch et al,21 2020 | Boston, MA; and, Philadelphia, PA | Broth microdilution | carbapenem-susceptible (meropenem MIC % 1 mg/L) | 2013-2016 | 119 | 119 (100) | 119 (100) | 109 (91.6) | |||||||
CZA: ceftazidime/avibactam; C/T: ceftolozane/tazobactam; MDR: multi-drug resistant; MEM: meropenem; NS: non-susceptible.
*All studies reported the isolates as susceptible if the MIC was % 8 mg/L for ceftazidime/avibactam and % 4 mg/L for ceftolozane/tazobactam.